Market capitalization | CHF810.29m |
Enterprise Value | CHF805.12m |
P/E (TTM) P/E ratio | 193.07 |
EV/FCF (TTM) EV/FCF | 41.33 |
EV/Sales (TTM) EV/Sales | 3.65 |
P/S ratio (TTM) P/S ratio | 3.68 |
P/B ratio (TTM) P/B ratio | 2.97 |
Revenue growth (TTM) Revenue growth | 11.42% |
Revenue (TTM) Revenue | CHF220.28m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Medartis:
1 Analyst has issued a forecast Medartis:
Jun '24 |
+/-
%
|
||
Revenue | 220 220 |
11%
11%
|
|
Gross Profit | 177 177 |
14%
14%
|
|
EBITDA | 26 26 |
34%
34%
|
EBIT (Operating Income) EBIT | 4.38 4.38 |
1,204%
1,204%
|
Net Profit | 4.03 4.03 |
161%
161%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Medartis Holding AG engages in the development, manufacture, and sale of medical devices for surgical fixation of bone fractures. It operates through the following geographical segments: EMEA, US, APAC, and LATAM. The company was founded by Thomas Straumann on November 3, 1997 and is headquartered in Basel, Switzerland.
Head office | Switzerland |
CEO | Matthias Schupp |
Employees | 876 |
Founded | 1997 |
Website | www.medartis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.